

HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Amy McNulty,

Acting Director, Division of the Executive Secretariat.

[FR Doc. 2017-25748 Filed 11-28-17; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Agency Information Collection Activities: Proposed Collection: Public Comment Request Information Collection Request Title: Health Professions Student Loan (HPSL) Program and Nursing Student Loan (NSL) Program Administrative Requirements (Regulations and Policy). OMB No. 0915-0047—Revision

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.

DATES: Comments on this ICR should be received no later than January 29, 2018.

ADDRESSES: Submit your comments to paperwork@hrsa.gov or mail the HRSA Information Collection Clearance Officer, Room 14N39, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: To request more information on the

proposed project or to obtain a copy of the data collection plans and draft instruments, email paperwork@hrsa.gov or call Lisa Wright-Solomon, the HRSA Information Collection Clearance Officer at (301) 443-1984.

SUPPLEMENTARY INFORMATION: When submitting comments or requesting information, please include the information request collection title for reference.

Information Collection Request Title: Health Professions Student Loan (HPSL) Program and Nursing Student Loan (NSL) Program Administrative Requirements (Regulations and Policy). OMB No. 0915-0047—Revision.

Abstract: The Health Professions Student Loan (HPSL) Program, as authorized by Public Health Service (PHS) Act sections 721-722 and 725-735, provides long-term, low-interest loans to students attending schools of medicine, osteopathic medicine, dentistry, veterinary medicine, optometry, podiatric medicine, and pharmacy. The Nursing Student Loan (NSL) Program, as authorized by PHS Act sections 835-842, provides long-term, low-interest loans to students who attend eligible schools of nursing in programs leading to a diploma, an associate degree, a baccalaureate degree, or graduate degree in nursing. It also contains a number of recordkeeping and reporting requirements for academic institutions and loan applicants. The applicable regulations for these programs under 42 CFR part 57 implement and detail the various statutory requirements (see chart below).

In an effort to consolidate information collection requests and achieve greater programmatic efficiency, HRSA is incorporating the Deferment-HRSA Form 519 and AOR-HRSA Form 501 (OMB No. 0915-0044) into this information collection request. As a result, the OMB No. 0915-0044 package will be discontinued.

Need and Proposed Use of the Information: Participating HPSL and NSL schools are responsible for determining eligibility of applicants, making loans, and collecting monies owed by borrowers on their outstanding loans. The Deferment Form (Deferment-HRSA Form 519), formerly incorporated under OMB No. 0915-0044, provides the schools with documentation of a

borrower's deferment status, as detailed for the HPSL program under 42 CFR part 57.210 and for NSL under 42 CFR part 57.310. The Annual Operating Report (AOR-HRSA Form 501), formerly incorporated under OMB No. 0915-0044, provides the Department of Health and Human Services (HHS) with information from participating schools (including schools that are no longer disbursing loans but are required to report and maintain program records, student records, and repayment records until all student loans are repaid in full and all monies due to the Federal Government are returned) relating to HPSL and NSL program operations and financial activities. Moreover, the HPSL and NSL program requirements are essential for assuring that borrowers are aware of their rights and responsibilities, academic institutions have accurate records of the history and status of each loan account in order to pursue aggressive collection efforts to reduce default rates, and that academic institutions maintain adequate records for audit and assessment purposes to help HHS safeguard federal funds made through the Federal Capital Contribution (FCC). Academic institutions are free to use improved information technology to manage the information required by the regulations.

Likely Respondents: Financial Aid Directors working at institutions participating in the HPSL and/or NSL Programs.

Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose, or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purpose of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the tables below.

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Instrument (HPSL & NSL)	Number of respondents	Responses per respondent	Total responses	Hours per response	Total burden hours
Deferment—HRSA Form 519	3,125	1	3,125	.5	1562.5
AOR—HRSA—Form 501	768	1	768	12	9,216
Total	3,893	3,893	10,778.5

* The deferment form is only used by the schools if a student requests a deferment. The AOR form is filled out for all grantees with a loan program at their school.

RECORDKEEPING REQUIREMENTS

Regulatory/section requirements	Number of recordkeepers	Hours per year	Total burden hours
<i>HPSL Program:</i>			
57.206(b)(2), Documentation of Cost of Attendance	432	1.05	454
57.208(a), Promissory Note	432	1.25	540
57.210(b)(1)(i), Documentation of Entrance Interview	432	1.25	540
57.210(b)(1)(ii), Documentation of Exit Interview	* 475	0.37	176
57.215(a) & (d), Program Records	* 475	10	4,750
57.215(b), Student Records	* 475	10	4,750
57.215(c), Repayment Records	* 475	19.55	9,286
HPSL Subtotal	475	20,496
<i>NSL Program:</i>			
57.306(b)(2)(ii), Documentation of Cost of Attendance	304	0.25	76
57.308(a), Promissory Note	304	0.5	152
57.310(b)(1)(i), Documentation of Entrance Interview	304	0.5	152
57.310(b)(1)(ii), Documentation of Exit Interview	* 486	0.14	68
57.315(a)(1) & (a)(4), Program Records	* 486	5	2,430
57.315(a)(2), Student Records	* 486	1	486
57.215(b)(3), Repayment Records	* 486	2.51	1,220
NSL Subtotal	486	4,584

* Includes active and closing schools. The HPSL and NSL programs are under two separate Titles VII and VII and CFDA numbers. The reporting requirements are items that are required of financial aid offices for administration of the loan programs at their school. HPSL data include active and closing Loans for Disadvantaged Students program schools.

REPORTING REQUIREMENTS

Regulatory/section requirements	Number of respondents	Responses per respondent	Total annual responses	Hours per response	Total burden hours
<i>HPSL:</i>					
57.206(a)(2), Student Financial Aid Transcript	4,600	1	4,600	0.25	1,150
57.208(c), Loan Information Disclosure	325	299.5	97,338	0.63	61,323
57.210(b)(1)(i), Entrance Interview	325	139.5	45,338	0.50	22,669
57.210(b)(1)(ii), Exit Interview	* 334	113.5	37,909	1.00	37,909
57.210(b)(1)(iii), Notification of Repayment	* 334	862.5	288,075	0.38	109,469
57.210(b)(1)(iv), Notification During Deferment	* 333	17	5,661	0.63	3,566
57.210(b)(1)(vi), Notification of Delinquent Accounts ...	334	172.5	57,615	1.25	72,019
57.210(b)(1)(x), Credit Bureau Notification	334	6	2,004	0.50	1,002
57.210(b)(4)(i), Write-off of Uncollectable Loans	520	1	520	3	1560
57.211(a), Disability Cancellation	3	1	3	1	3
57.215(a), Administrative Hearings record retention	0	0	0	0	0
57.215(a)(2), Administrative Hearings reporting re- quirements	0	0	0	0	0
HPSL Subtotal	310,670
<i>NSL:</i>					
57.306(a)(2), Student Financial Aid Transcript	4,100	1	4,100	0.25	1,025
57.310(b)(1)(i), Entrance Interview	282	17.5	4,935	0.42	2,073
57.310(b)(1)(ii), Exit Interview	348	9	3,132	0.42	1,315
57.310(b)(1)(iii), Notification of Repayment	348	9	3,132	0.27	846
57.310(b)(1)(iv), Notification During Deferment	348	1.5	522	0.29	151
57.310(b)(1)(vi), Notification of Delinquent Accounts ...	348	42.5	14,790	0.04	592
57.310(b)(1)(x), Credit Bureau Notification	348	709	246,732	0.006	1,480
57.310(b)(4)(i), Write-off of Uncollectable Loans	23	1	23	3	69

REPORTING REQUIREMENTS—Continued

Regulatory/section requirements	Number of respondents	Responses per respondent	Total annual responses	Hours per response	Total burden hours
57.311(a), Disability Cancellation	16	1	16	1	16
57.315(a)(1)(ii), Administrative Hearings	0	0	0	0	0
57.316(a), Administrative Hearings	0	0	0	0	0
NSL Subtotal					7,567

HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions, (2) the accuracy of the estimated burden, (3) ways to enhance the quality, utility, and clarity of the information to be collected, and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Amy McNulty,

Acting Director, Division of the Executive Secretariat.

[FR Doc. 2017-25750 Filed 11-28-17; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Concatenated L2 Peptide Based Human Papillomavirus Vaccines

AGENCY: National Institutes of Health.

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to BravoVax Co., Ltd located in Wuhan, China.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 14, 2017 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated exclusive license should be directed to: Kevin W. Chang, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC

9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-9702 Telephone: (240)-276-6910; Facsimile: (240)-276-5504 Email: changke@mail.nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

United States Provisional Patent Application No. 60/649,249 filed February 1, 2005 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Reference No. E-103-2005/0-US-01]; United States Provisional Patent Application No. 60/697,655 filed July 7, 2005 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Reference No. E-103-2005/1-US-01]; United States Provisional Patent Application No. 60/752,268 filed December 21, 2005 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Reference No. E-103-2005/2-US-01]; International PCT Application No. PCT/US2006/003601 filed February 1, 2006, and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Reference No. E-103-2005/3-PCT-01]; United States Patent No. 8,404,244, issued March 26, 2013 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Ref. No. E-103-2005/3-US-10]; Canadian Patent No. 2,596,698 issued May 16, 2017 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Ref. No. E-103-2005/3-CA-03]; Australian Patent No. 2006210792 issued November 8, 2012 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-

neutralizing Antibodies" [HHS Ref. No. E-103-2005/3-AU-04]; Japanese Patent No. 5224821 issued March 22, 2013 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Ref. No. E-103-2005/3-JP-05]; Brazilian Patent Application No. PI0607097-3 filed February 1, 2006 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Ref. No. E-103-2005/3-BR-06]; Chinese Patent No. 200680011079.1 issued March 27, 2013 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Ref. No. E-103-2005/3-CN-07]; Indian Patent No. 263255 issued October 16, 2014 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Ref. No. E-103-2005/3-IN-08]; European Patent No. 1853307 issued December 14, 2016 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Ref. No. E-103-2005/3-EP-09]; German Patent No. 1853307 issued December 14, 2016 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Ref. No. E-103-2005/3-DE-11]; French Patent No. 1853307 issued December 14, 2016 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Ref. No. E-103-2005/3-FR-12]; and United Kingdom Patent No. 1853307 issued December 14, 2016 and entitled, "Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies" [HHS Ref. No. E-103-2005/3-GB-13]. The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to the use of Licensed Patent Rights for the following: "Development and use of